Fcα R expression on polymorphonuclear leukocyte and superoxide generation in IgA nephropathy  by Kashem, Abul et al.
Kidney International, Vol. 45 (1994), pp. 868—875
Fca R expression on polymorphonuclear leukocyte and
superoxide generation in IgA nephropathy
ABUL KASHEM, MASAYUKI ENDOH, YASUO NoMoTo, HIDETO SAKAI, and HIROE NAKAZAWA
Division of Nephrology and Metabolism, Department of Internal Medicine, and Department of Physiology, Tokai University, Isehara,
Kanagawa, Japan
FcaR expression on polymorphonuclear leukocyte and superoxide
generation in IgA nephropathy. Superoxide (02) production and FcaR
antigen expression of circulating polymorphonuclear leukocytes
(PMNL) isolated from patients with IgA nephropathy (IgAN) and
non-IgA mesangial proliferative glomerulonephritis (PGN) and healthy
volunteers were investigated to establish their biological importance in
the immunopathogenesis of mesangial proliferative glomerulonephritis.
PMNL from both patient groups showed increased 02 production
when stimulated with N-formyl methionyl leucyl phenylalanine (FMLP)
and phorbol myristate acetate (PMA). The increased 02 generation
demonstrated a positive correlation with the degree of proteinuria.
Aggregated IgA caused enhanced 02 production only in patients with
IgAN who also showed a significant correlation with proteinuria.
Increased expression of FcaR on circulating PMNL was observed in
IgAN patients as determined by flow cytometric analysis. The amount
of FcaR on PMNL was positively correlated with 02 generation
triggered with IgA aggregates. These results suggest that (1.) circulating
PMNL may potentially be participating in the pathogenesis of glomer-
ular injury in mesangial proliferative glomerulonephritis, and (2.) IgA
aggregates/immune complexes may contribute to the immunopathogen-
esis of IgAN through augmenting the Fca receptor-mediated generation
of superoxide anion.
In the past few years, increasing evidence has accumulated
suggesting the contribution of polymorphonuclear leukocytes
(PMNL) in the pathogenesis of both immune-mediated and
nonimmune-mediated glomerular diseases. One of the impor-
tant findings to support PMNL participation is the recent
demonstration of PMNL infiltration in the glomeruli of various
types of nephntis [1—4].
When PMNL are activated, they release not only proteases
but also superoxide anion (02) [5—7]. In the presence of
myeloperoxidase or iron, 02 is catalyzed into more toxic and
active oxygen species, such as hyphochlorous acids and hy-
droxyl radicals, which can cause functional and structural
abnormalities in glomerular inflammation [8]. A recent study
showed that aggregated IgG and IgA obtained from IgA ne-
phropathy (IgAN) patients induced greater 02 production in
PMNL of healthy controls than the immune aggregates ob-
tained from other healthy controls [9]. Therefore, the potential
role of circulating IgG and IgA immunoglobulins was indicated
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as an underlying mechanism for the activation of PMNL.
However, the reaction of PMNL from IgAN patients to IgG and
IgA aggregates has not yet been studied. Moreover, the corre-
lation between the activities of PMNL and the severity of
glomerular damage has never been studied.
In this paper, we measured 02 generation from PMNL of
IgAN patients to demonstrate the primed state of PMNL in
IgAN. A detailed study was performed to determine the rela-
tionship between 02 generation and receptor expression for
IgG (Pcy) and for IgA (Fca) as a causative factor for the
activation of PMNL in IgAN. We measured 02 generation
from PMNL of non-IgA mesangial proliferative glomerulone-
phritis (PGN) patients and healthy volunteers as a comparison.
Despite the clinicopathological similarity to IgAN, the PGN
group was included to differentiate the functional significance of
IgA-immune complexes and FcaR in these diseases. As a
method of superoxide generation, we used an MCLA-depen-
dent chemiluminescence system by which °2 could be quan-
tified with high specificity and reliability [10, 11]. The expres-
sion of FcaR on PMNL was studied by flow cytometry using a
monoclonal antibody, My-43. The peak 02 generation by
PMNL was compared with the amount of urine protein to
evaluate their participation in the inflammatory process of
mesangial proliferative glomerulonephritis.
Subjects
A total of 45 patients with IgA nephropathy (35 males and 10
females; mean age 36 years) and 40 patients with non-IgA
mesangial proliferative glomerulonephritis (PGN, 25 males and
15 females; mean age 36 years) with clinical and renal immu-
nopathogenic diagnosis were enrolled in the present study.
Patients with other systemic diseases as well as other prolifer-
ative glomerulonephritis (GN), such as membranoproliferative
GN, endocapillary GN and crescentic GN, were excluded from
this study. Serum creatinine of all patients was below 2 mg%.
None of the patients was on corticosteroid or any immunosup-
pressive therapy during this study. None of these patients
showed any clinical signs of infection, including tonsillitis and
colitis, within two months prior to the study. Clinical status of
the patients was assessed by estimating the urinary output of
total protein in 24 hours (UTP), severity of hematuria, serum
creatinine level, serum creatinine clearance (GFR) and serum
immunoglobulins (Igs). Severity of renal tissue damage was
scored histologically. None of our patients with IgAN displayed
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Fig. 1. MCLA-dependent O production triggered by FMLP (0) and
PMA (u). Abbreviations are: IgAN, IgA nephropathy patients; PGN,
non-IgA mesangial proliferative glomerulonephritis patients. The 02
production was significantly higher in IgAN and PGN patients in
response to both stimuli compared with that in control group. Re-
sponses to FMLP and PMA did not differ. The vertical error bars
represent the mean SD. *D < 0.005; ** P < 0.001.
any ANCA activity in their sera (assayed by indirect immuno-
fluorescence method). The IgAN patients included in this study
were in a clinically and histologically quiescent state. Sixty age-
matched healthy volunteers (45 males and 15 females) were
used as donors of control peripheral blood polymorphonuclear
leukocytes (PMNL).
Preparation of polymorphonuclear leukocytes
The heparinized peripheral venous blood was subjected to
simple Hemaceel® (3.5%) sedimentation for 30 to 45 minutes at
37°C to hasten erythrocyte precipitation. Then PMNL were
separated from mononuclear cells using Ficoll-Hypaque density
centrifugation for 30 minutes at 1500 revolutions per minute
(rpm). The PMNL rich fluid at the interface of red blood cell
sedimentation was aspirated and washed twice with calcium
and magnesium-free Hank's balanced salt solution (HBSS).
Erythrocyte contamination was removed by hypotonic shock.
The final preparation was washed again with HBSS and
resuspended in the same solution on ice until next assay. The
viability of PMNL was more than 98% as assessed by Trypan
blue exclusion. The final cell preparation contained 90 to 95%
neutrophils, the rest of the cells being mononuclear cells and
eosinophils.
Reagents
The following reagents were used in this study: Hemaceel®
(3.5%) (Behring Inst. Erbehring, Germany), Ficoll-Hypaque
(Pharmacia LKB Biotechnology Inc., Piscataway, New Jersey,
USA), Hank's balanced salt solution (Gibco, Grand Island,
New York, USA), phorbol myristate acetate (PMA, 1 mg!ml),
N-formyl-L-methionyl-L-leucyle-L-phenylalanine (FMLP, 3 X
10—8 M/ml; Sigma Chemical Co., St. Louis, Missouri, USA),
2-methyl-6 [p-methoxyphenol]-3,7-dihydroimidazo [1, 2-a]
pyrazin-3-one (MCLA, 3 jsM/ml; Nihon Zoki, Osaka, Japan)
and Cytochrome c (Boehringer Mannheim GmbH, Germany)
were purchased. Recombinant human superoxide dismutase
(SOD) was a donation from Nihon Kayaku Co. (Tokyo, Japan).
Immuno globulins and monoclonal antibody
Human monomeric IgA (IgAl, lambda) was prepared in our
laboratory from serum of a myeloma patient using a Jacalin
column [121. Briefly, IgA rich fraction was precipitated by 50%
ammonium sulfate saturation, and was applied to a Jacalin
column (sepharose 4B coupled with extracted protein from the
seeds of the jack fruit). After washing with borate buffered
saline, IgA was eluted with 0.8 M galactose solution. Purified
IgA showed a single precipitating line against anti-whole human
serum examined by immunoelectrophoresis, and was found not
to be contaminated with IgG or 1gM when examined by ELISA.
Human normal IgG (10 mglml) was purchased from Green
Cross Co. (Osaka, Japan). Aggregates of immunoglobulins were
made by heating IgG and IgA in PBS (pH 7.4) for 20 minutes
and 90 minutes, respectively, at 63°C which was found in a
previous experiment to give an optimum amount of soluble
aggregates [13]. Fluorescence isothiocyanated (FITC) goat
F(ab')2 anti-mouse Igs was purchased from Tago, Inc. (Burlin-
game, California, USA). A monoclonal antibody specific for
IgA Fca receptor, My-43, was a gilt from Dr. Li Shen (Dept. of
Microbiology, Dartmouth Medical School, Hanover, New
Hampshire, USA) [14].
Superoxide assay
Superoxide generation was quantified by measuring 02-
dependent chemiluminescence (CL) using a Hamamatsu C1230
Photon counter with an H-R550 photomultiplier (Hamamatsu
Photonics Co. Ltd., Japan; applied potential 1.5 kV) as de-
scribed previously [10, 11]. Briefly, 2.5 to 5.0 x tO4 cells were
kept into a Petridish (50 mm x 9 mm; Falcon, Lincoln Park,
New Jersey, USA) containing 10 d (20 ,sM) of MCLA in warm
HBSS on initial measurement. All procedures of the chemilu-
minescence method were conducted at 37°C. After obtaining a
basal photon count, 10 d of either FMLP (6 x l0 '°M) or PMA
(10 sg) or 10 l of heat aggregated IgG (10 mg/ml)IIgA (10
mglml) was added as a stimulant at the 30th second of cell
addition. Each stimulant was used separately to trigger PMNL
O2 production. Changes in photon counts were monitored
until they reached the plateau level, which was observed within
1.5 to 5 minutes after addition of a stimulant (depending on the
nature of the stimulant) and terminated by adding 100 pi (236
sgIml) of SOD. Photon counts caused by activated PMNL
decreased to the level of basal counts by SOD at the concen-
tration used in the experiment, indicating that photon counts in
MCLA chemiluminescence were 02-dependent. The peak
counts of SOD-inhibitable chemiluminescence per cell were
used to express the relative amount of 0 generation. The rate
of 02 generation in this condition was determined by compar-
ing the corresponding value obtained by the cytochrome c
reduction method [151 and 7.52 CPS/cell was shown to be
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comparable to 1 nm/mm/cell. All measurements were per-
formed in triplicate. PMNL isolation took less than two hours
and CL study was completed within two hours after cell
isolation to avoid time dependent decrease of cell functions.
Flow cytometry
Flow cytometric analysis was performed using a FACScan
analyzer (Becton Dickinson, Mountain View, California, USA)
by forward light scattering (FSC) profile and side light scatter-
ing (SSC) profile. Five hundred thousand PMNL were stained
with monoclonal antibody for FeaR, My-43. After 30 minutes
on ice, cells were washed with 1% bovine serum albumin (BSA)
in phosphate buffered saline (PBS) and stained with FITC
labeled goat anti-mouse Igs for another 30 minutes. After final
washing cells were fixed with 2% paraformyldehyde (PFA) and
kept at 4°C until flow cytometnc analysis. Mouse control
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Fig. 4. 02 productions triggered by heat aggregated IgG (0) and IgA
() immunoglobulins. Aggregated IgA elicited a significantly higher
response (*P < 0.01) only in the IgAN group compared with the PGN
and healthy groups. Response to aggregated IgG showed no significant
variation in any group. The vertical error bars represent the mean SD.
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Fig. 2. Comparison between the CL-peaks
and the amount of proteinuria in patients with
IgAN. Significant correlations for FMLP
activation (P < 0.005, A) and for PMA
activation (P < 0.01, B) were observed. A. y
= 0.219x — 0.406; r = 0.809; P z 0.005. B. y
= 170x — 0.045; r = 0.600; P < 0.01.
Fig. 3. Relationship between the CL-peaks
and the amount of proreinuria in PGN
patients. A positive correlation between
O2production and proteinuria was observed
for both stimulants (P < 0.01). A. y = 0197x
— 0.068; r = 0.599; P < 0.01. B. y 0202x —
0.233; r = 0.698; P < 0.01.
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Fig. 6. Amount of FcaR expression on PMNL in IgAN, PGN and
controls. MFV, Mean fluorescence value. Expressions of FeaR anti-
gens (ordinate) were significantly increased in patients with IgAN
compared with those in PGN patients and controls. Horizontal bars
indicate the mean.
immunogiobulin was used in the staining assays as a negative
control to determine the background binding of mouse 1g.
Induction study
In this experiment, PMNL were incubated in RPMI 1640
media containing 10% heat-inactivated fetal calf serum (FCS)
with 2 ifiM L-glutamine, 100 jslml penicillin, 100 mg/mi strepto-
mycin and 5 mm HEPES buffer (Gibco). PMNL (2 x 106/ml)
from healthy controls were incubated with human monomeric
myeloma IgA (300 g/ml), heat aggregated IgA (300 .tg/ml) and
in media alone for 2 hours, 6 hours, 10 hours and 16 hours at
37°C with 5% C02, as incubated by other laboratories [16—18].
Then flow cytometric analysis of FcaR expression was per-
formed. All procedures used in this study were performed with
endotoxin free media and supplies to avoid non-specific activa-
tion of PMNL. Procedures for cell staining and flow cytometric
analysis were the same as above. Cells were washed with
HBSS after incubation and cell viability was found to be more
than 90% as assessed by Trypan blue exclusion.
Statistics
P values of all correlation assays were calculated by using the
Sperman-Kendall test. The Mann-Whitney U test and Fisher
test were applied to calculate the P value among different
groups. All results were expressed as mean SD.
Results
The background chemiluminescence values of PMNL prior
to stimulation were basically similar in controls and patients,
suggesting that the PMNL were not activated during the isola-
tion procedure.
A preliminary study was done to determine the dose of
different stimulants used in this study for optimal chemilumi-
nescence responses (data not shown). The average CL-peaks of
PMNL, isolated from healthy subjects, IgAN and PGN patients
were 2.83 1.55, 6.23 2.37 and 5.08 2.41 cps per cell,
respectively, for FMLP stimulation and 3.30 1.52, 6.12
2.06 and 5.90 1.60 cps per cell, respectively, for PMA
stimulation (Fig. 1). Patterns of the time course of responses to
both stimuli were almost identical and parallel. The CL-peaks
were compared with the degree of proteinuria in both patient
groups. A positive correlation between these two parameters
was observed in IgAN patients (P < 0.005 for FMLP; P < 0.01
for PMA) as well as in PGN patients (P <0.01 for FMLP; P <
0.01 for PMA) as shown in Figures 2 and 3, respectively. Other
clinical data, such as hematuria, serum creatinine level, GFR,
and histologically determined grading of tissue damage did not
show any significant correlation with the CL counts (data not
shown).
The CL-peaks upon activation with heat aggregated immu-
noglobulins, IgG and IgA in the three groups are shown in
Figure 4. IgG aggregates triggered a tendency of higher CL-
peaks (1.80 0.57, 1.58 0.75 and 1.67 0.69 cps) compared
to those triggered by an equivalent dose of aggregated IgA (1.77
0.71, 0.99 0.39 and 1.00 0.34) in IgAN patients, PGN
patients and control group, respectively. However, statistically
there was no difference in CL-peaks triggered by lgG among the
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02 production to immune aggregates and
degree of proteinuria in patients with IgAN.
Response to aggregated IgA showed a positive
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Table 1. Expression of FcaR on PMNL when incubated overnight
with or without IgA supplement
Experiment
no.
Fresh
PMNL
Incubated PMNL
only in
media
with IgA
protein
with
aggregated
IgA
1
2
3
Mean
41
48
43
44 3.6
39
28
35
34 5.5
44
46
40
43.33 3.1
68
62
60
63.33 4.16a
a P < 0.05
Total amounts of FcaR expresssion detected by flow cytometry was
significantly increased when PMNL was incubated with IgA aggregates
(300 gIml), compared with monomeric IgA treated (300 gIml) or
media alone treated cells. Results are expressed as the mean fluores-
cence value (MFV).
three groups. IgA aggregates caused significantly higher CL-
peaks (1.77 0.71 cps) only in IgAN (P <0.01) when compared
with the responses in the PGN group (0.99 0.39 cps) and
control group (1.00 0.34 cps). The CL-peaks in the PGN
group were comparable to those in the control group. A
comparison between the CL-peaks for immune, aggregates and
degree of proteinuria in IgAN group is shown in Figure 5 (A and
B). A significant correlation was observed only when triggered
by IgA aggregates (P < 0.01) but not by IgG aggregates. PGN
patients did not show any correlation between these two
parameters in response to either immune aggregate (data not
shown).
Figure 6 demonstrates the flow cytometric analysis in mean
fluorescence value (MFV) for FcaR expression on circulating
PMNL using an anti-FcaR antibody, My-43. The FcaR antigen
expression was significantly increased in patients with IgAN
(MFV = 60.12 18.49 per cell) compared to that in PGN
patients (MFV 43.53 17.12 per cell) and the healthy group
(MFV = 43.59 10.06 per cell). To evaluate the potential
biological role of FcaR in PMNL, parallel studies of FcaR
expression and 02 generation triggered by immunoglobulin
aggregates were performed in 22 IgAN patients and 18 controls
(Fig. 7, A and B). The amount of FcaR expression correlated
with O, production triggered by IgA aggregates in IgAN
Fig. 7. Correlation between the quantity of
superoxide production and percentage of
FcaR expressions on PMNL in the same
individual when activated with aggregated
immunoglobulins. Symbols are: (0) IgAN; (•)
control. Response to IgA aggregates showed a
linear correlation in the production of 02
with the increase in FeaR number (A, P <
0.01; y = 1.9E — 2x + 0.03, r 0.637.),
compared with the IgG response (B, P = NS).
patients (P < 0.025). However, 02 production triggered by
IgG aggregates did not show any significant correlation with the
amount of IgA receptor.
To determine the influence of IgA on PMNL function, an
additional study was performed using PMNL from three
healthy volunteers. Total FcaR expression on fresh (resting)
PMNL and PMNL incubated in media alone, with monomeric
IgA and with IgA aggregates were analyzed by flow cytometry.
Mean fluorescence value of PMNL treated with aggregated IgA
showed an increased expression of FcaR compared to that
incubated with monomeric IgA or in media alone (Table 1).
With two hours of incubation, an increase in FeaR was ob-
served which peaked by 10 hours and did not increase signifi-
cantly with further extension of the incubation period (data not
shown). The individual values of the rate of FcaR induction
showed a marked variation among the three groups, but in each
case, IgA aggregates induced FeaR expression significantly
above the media level or monomeric IgA treated level.
Although PMNL accumulation in the glomeruli was likely to
be more in acute stage of IgAN, we also observed a few such
cell under light microscopy in some glomeruli of IgAN even in
clinically quiescent state of the disease (Fig. 8).
Discussion
This study demonstrated that circulating PMNL of mesangial
proliferative glomerulonephritis patients with or without me-
sangial IgA deposits generate O2 in significantly greater
amounts than the control group in response to either FMLP or
PMA stimulus. A positive correlation was observed between
the amount of O2 production and the severity of proteinuria
which is considered as one of the indicators of glomerular
basement membrane (GBM) injury. The increased PMNL 02
production in response to different stimulants and their positive
correlation with proteinuria may be due to the presence of some
common mechanism, in addition to the disease specific one,
that damages the GBM in both IgA nephropathy and PGN. A
previous report suggested that O2 may be the most important
mediator among reactive oxygen species released by activated
neutrophils in the damaged kidney [19]. Therefore, 02 is an
important tool for the functional activity of PMNL, and glomer-
ular injury at least in part may be due to 02 generation in
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Fig. 8. PMNL infiltration (light microscopy) in the glomerulus of IgA nephropathy (shown by an arrow head).
mesangial proliferative glomerulonephritis with or without me-
sangial IgA deposits.
Accumulation of PMNL in the glomeruli in the acute phase of
IgAN [41, and the correlation between PMNL accumulation and
histologically defined grading of glomerular damage in IgAN
patients [201 support the participation of PMNL in glomerulo-
nephritis. In addition, we usually observe infiltration of a few
PMNL in some glomeruli of IgAN patients even in the clinically
quiescent state of the disease (Fig. 8). Although activity of
PMNL may be higher in the acute phase of IgAN, our and other
[20] findings support their participation in the inactive phase as
well. The exact mechanism of PMNL accumulation and activa-
tion in the glomeruli is not known, but it can be caused by
chemoattractants released from both infiltrating and residual
glomerular cells during glomerular inflammation [211. Recent
data document a link between glomerular infiltration of mono-
cytes/macrophages and the severity of glomerular destruction
and mesangial proliferation in IgAN [18] as well as the duration
and severity of proteinuria in experimental immune complex
glomerulonephritis [22]. Cytokines derived from these cells
may be possible chemoattractants and/or priming agents for
PMNL.
Our results also indicate that PMNL in glomerulonephritis
were in the primed state which enables PMNL to produce more
02 upon activation with a second stimulant. Major cytokines,
such as IL-i (interleukin-1), IL-2 (interleukin-2), TNF (tumor
necrosis factor), INF-y (interferon gamma) and CSF (colony
stimulating factor) have been shown to have a PMNL priming
effect [23—25], some of which was reported to be raised in the
serum of glomerulonephntis patients [261. Therefore, these are
plausible priming agents in both IgAN and PGN patients.
However, IgA immune complexes showed a priming effect only
in IgAN patients, and the underlying mechanism of this is either
an increase in the number of FcaR or an increase in the affinity
of the receptors to the agonist. Our results showing a positive
correlation between the increased amount of FcaR and in-
creased 02 generation support the former notion. In addition,
higher O production induced by IgA immune aggregates
showed a correlation with the amount of proteinuria only in
IgAN. Patients with PGN did not show such a correlation.
In a flow cytometric analysis, increased FcaR expression on
PMNL from patients with IgAN was observed despite the
clinical quiescent state of the disease. Previous studies showed
an increased expression of these receptors on lymphocytes [27]
and monocytes (own observation, unpublished data) in patients
with IgAN. The precise mechanism of FcaR expression and its
functional significance in IgAN are not well defined. Receptor
expression appears to be constitutive but can be selectively
up-regulated on different phagocytic cells (neutrophils and
monocytes/macrophages) by stimulation with chemoattractants
a&(
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and polymeric IgA [28, 29]. IgA receptor may play important
roles in the regulatory and effector phase of immune responses.
For instance, T cells expressing FcaR may be involved in the
regulation of IgA secretion [30]. Our observation of increased
PMNL 02 to IgA aggregates, and hence increased proteinuria,
parallel to the PMNL FcaR expression in IgAN patients
accounts for the effector function of this receptor in IgAN. Our
data are in agreement with previous observations, since binding
of IgA immune complexes/antibody to FcaR cells has been
shown to trigger phagocytosis [31] and oxidative burst [141.
Aggregated IgG-induced 02 production did not show such a
correlation. The correlation between IgA receptors and O2
production to IgA aggregates indicated that there is an overall
enhancement in the responsiveness of the oxidase system of
02 generation which is probably related to the increased
signaling from increased FcaR. Moreover, this isotype-specific
activation of FcaR with IgA aggregates also confirms the
biological activity of human IgA, thus facilitating interactions
between cells with FcaR and IgA immune complexes which is
one of the possible immunological events in IgAN.
In an incubation study, aggregated IgA induced an increase in
FcaR expression on PMNL compared to monomeric IgA (same
dose). Therefore, only polymeric IgA and not monomeric IgA
was able to induce FcaR expression efficiently on PMNL
(Table I). An increase in FcaR expression (within 2 hours of
incubation) with its maximum value by 10 hours, demands a
detailed study to determine if the increase of the receptors in
activated PMNL was caused by either new protein synthesis or
translocation of presynthesized receptors from intracellular
pools, or both mechanisms. Mean serum IgA level in IgAN
patients (N = 40) was markedly higher (378 103 mg) than that
in PGN patients (303 128 mg, N = 40) and in controls (290
80 mg, N = 40), but there was no correlation between individual
serum IgA levels and PMNL FcaR expression (data not
shown). The possible explanation for this negative correlation is
that the molecules responsible for FcR induction on PMNL
might be polymeric IgA aggregates/immune complexes present
in IgAN serum [32] and in mesangium [33], but not the
monomeric form, since the major component of serum IgA is
monomeric in nature [34]. Recently, Lai and Leung [91 showed
the ability of IgA aggregates obtained from IgAN patients to
increase 02 generation and calcium mobilization in neutro-
phils of healthy controls. The mesangial IgA deposits, a hall-
mark of IgAN, could be associated with the presence of
circulating IgA aggregates/immune complexes and might have a
distinctive role in the development and/or progression of IgAN
as compared with non-IgA proliferative GN.
The present study allows us to consider the following sce-
nario: (1) some unknown inflammatory substances including
immune complexes trigger monocyte/macrophage infiltration in
the glomeruli; (2) then cytokines, such as IL-l, IL-2, IL-8, TNF
and CSF are released from these cells; (3) these cytokines and
IgA immune complexes induce PMNL accumulation and acti-
vation in the glomeruli; and (4) finally, activated PMNL pro-
duce superoxide in situ, accelerating the glomerular damage.
More extensive studies are required to determine if the primed
condition of the circulating PMNL with increased FcaR is
either a cause or consequence of this disease.
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